Literature DB >> 21037275

CANT1 mutation is also responsible for Desbuquois dysplasia, type 2 and Kim variant.

Tatsuya Furuichi1, Jin Dai, Tae-Joon Cho, Satoru Sakazume, Masahide Ikema, Yoshito Matsui, Gareth Baynam, Toshiro Nagai, Noriko Miyake, Naomichi Matsumoto, Hirofumi Ohashi, Sheila Unger, Andrea Superti-Furga, Ok-Hwa Kim, Gen Nishimura, Shiro Ikegawa.   

Abstract

BACKGROUND: Desbuquois dysplasia (DD) is a recessively inherited condition characterised by short stature, generalised skeletal dysplasia and advanced bone maturation. DD is both clinically and radiographically heterogeneous, and two subtypes have been distinguished based on the presence (type 1) or absence (type 2) of an accessory metacarpal bone. In addition, an apparently distinct variant without additional metacarpal bone but with short metacarpals and long phalanges (Kim variant) has been described recently. Mutations in the gene that encodes for CANT1 (calcium-activated nucleotidase 1) have been identified in a subset of patients with DD type 1.
METHODS: A series of 11 subjects with DD from eight families (one type 1, two type 2, five Kim variant) were examined for CANT1 mutations by direct sequencing of all coding exons and their flanking introns.
RESULTS: Eight distinct mutations were identified in seven families (one type 1, one type 2 and all 5 Kim variant): three were nonsense and five were missense. All missense mutations occurred at highly conserved amino acids in the nucleotidase conserved regions of CANT1. Measurement of nucleotidase activity in vitro showed that the missense mutations were all associated with loss-of-function.
CONCLUSION: The clinical-radiographic spectrum produced by CANT1 mutations must be extended to include DD type 2 and Kim variant. While presence or absence of an additional metacarpal ossification centre has been used to distinguish subtypes of DD, this sign is not a distinctive criterion to predict the molecular basis in DD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21037275     DOI: 10.1136/jmg.2010.080226

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  16 in total

1.  A Report of Novel STIM1 Deficiency and 6-Year Follow-Up of Two Previous Cases Associated with Mild Immunological Phenotype.

Authors:  Laura Rice; Claire Stockdale; Ian Berry; Sean O'Riordan; Karen Pysden; Rashida Anwar; Roger Rushambuza; Moira Blyth; Sonal Srikanth; Yousang Gwack; Yasser M El-Sherbiny; Clive Carter; Sinisa Savic
Journal:  J Clin Immunol       Date:  2019-04-04       Impact factor: 8.317

2.  Novel and recurrent XYLT1 mutations in two Turkish families with Desbuquois dysplasia, type 2.

Authors:  Long Guo; Nursel H Elcioglu; Aritoshi Iida; Yasemin K Demirkol; Seda Aras; Naomichi Matsumoto; Gen Nishimura; Noriko Miyake; Shiro Ikegawa
Journal:  J Hum Genet       Date:  2016-11-24       Impact factor: 3.172

3.  Desbuquois dysplasia type I and fetal hydrops due to novel mutations in the CANT1 gene.

Authors:  Franco Laccone; Katharina Schoner; Birgit Krabichler; Britta Kluge; Robin Schwerdtfeger; Bernt Schulze; Johannes Zschocke; Helga Rehder
Journal:  Eur J Hum Genet       Date:  2011-06-08       Impact factor: 4.246

4.  Ca2+-activated nucleotidase 1, a novel target gene for the transcriptional repressor DREAM (downstream regulatory element antagonist modulator), is involved in protein folding and degradation.

Authors:  Tito Calì; Laura Fedrizzi; Denis Ottolini; Rosa Gomez-Villafuertes; Britt Mellström; Jose R Naranjo; Ernesto Carafoli; Marisa Brini
Journal:  J Biol Chem       Date:  2012-03-26       Impact factor: 5.157

5.  A newly recognized syndrome with characteristic facial features, skeletal dysplasia, and developmental delay.

Authors:  Wagner A R Baratela; Michael B Bober; George E Tiller; Ericka Okenfuss; Colleen Ditro; Angela Duker; Deborah Krakow; Deborah L Stabley; Katia Sol-Church; William Mackenzie; Ralph Lachman; Charles I Scott
Journal:  Am J Med Genet A       Date:  2012-06-18       Impact factor: 2.802

6.  MED resulting from recessively inherited mutations in the gene encoding calcium-activated nucleotidase CANT1.

Authors:  Karthika Balasubramanian; Bing Li; Deborah Krakow; Lisette Nevarez; Patric J Ho; Julia A Ainsworth; Deborah A Nickerson; Michael J Bamshad; LaDonna Immken; Ralph S Lachman; Daniel H Cohn
Journal:  Am J Med Genet A       Date:  2017-07-25       Impact factor: 2.802

7.  Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP.

Authors:  Lisenka E L M Vissers; Ekkehart Lausch; Sheila Unger; Ana Belinda Campos-Xavier; Christian Gilissen; Antonio Rossi; Marisol Del Rosario; Hanka Venselaar; Ute Knoll; Sheela Nampoothiri; Mohandas Nair; Jürgen Spranger; Han G Brunner; Luisa Bonafé; Joris A Veltman; Bernhard Zabel; Andrea Superti-Furga
Journal:  Am J Hum Genet       Date:  2011-05-05       Impact factor: 11.025

8.  XYLT1 mutations in Desbuquois dysplasia type 2.

Authors:  Catherine Bui; Céline Huber; Beyhan Tuysuz; Yasemin Alanay; Christine Bole-Feysot; Jules G Leroy; Geert Mortier; Patrick Nitschke; Arnold Munnich; Valérie Cormier-Daire
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

9.  Exome sequencing reveals two novel compound heterozygous XYLT1 mutations in a Polish patient with Desbuquois dysplasia type 2 and growth hormone deficiency.

Authors:  Aleksander Jamsheer; Ewelina M Olech; Kazimierz Kozłowski; Marek Niedziela; Anna Sowińska-Seidler; Monika Obara-Moszyńska; Anna Latos-Bieleńska; Marek Karczewski; Tomasz Zemojtel
Journal:  J Hum Genet       Date:  2016-03-31       Impact factor: 3.172

10.  First Report of Two Egyptian Patients with Desbuquois Dysplasia due to Homozygous CANT1 Mutations.

Authors:  Manal M Thomas; Engy A Ashaat; Ghada A Otaify; Samira Ismail; Mona L Essawi; Mohamed S Abdel-Hamid; Heba A Hassan; Sonia A Alsaiedi; Mona Aglan; Mona O El Ruby; Samia Temtamy
Journal:  Mol Syndromol       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.